CoChat

Cardiac Resynchronization Therapy May Benefit Patients with Left Ventricular Ejection Fraction >35%: A PROSPECT Trial Substudy

Open access
Chung, Eugene S., Katra, Rodolphe P., Ghio, Stefano, Bax, Jeroen, Gerritse, Bart, Hilpisch, Kathryn, Peterson, Brett J., Feldman, David S., Abraham, William T. · 2010 · European Journal of Heart Failure
Cited by 125

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Aims: Cardiac resynchronization therapy (CRT) is currently limited to those with left ventricular ejection fraction (LVEF) ≤35%. To evaluate whether patients with LVEF >35% might benefit from CRT, we performed a retrospective analysis of the predictors of response to CRT (PROSPECT) database. Methods and results: PROSPECT was a prospective, multicentre study that enrolled CRT patients based on enrolling centre-evaluated LVEF <35%, but all echocardiograms were subsequently analysed by a core laboratory. Patients with core laboratory-measured LVEF >35% (OVER35) were compared with those whose LVEF was <35% (UNDER35). Clinical composite score (CCS) and change in LV end systolic volume (LVESV) were analysed from baseline to 6-month follow-up. Of 361 patients, 86 (24%) had LVEF >35%. At entry, OVER35 had smaller LV volumes, shorter QRS duration, shorter 6-min walk distance, and were more likely to have ischaemic aetiology than UNDER35. Outcomes were comparable between the groups, with 62.8% of OVER35 improved in CCS (70.2% in UNDER35) and 50.8% of OVER35 improved in LVESV (57.8% in UNDER35). Conclusion: Patients with LVEF >35%, New York heart association functional Class III–IV status, and QRS >130 ms appear to derive clinical and structural benefit from CRT. As CRT may offer a valuable option for these patients, this hypothesis should be formally tested in a prospective, randomized multicentre trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurjhf/hfq009

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 125

Metadata

Authors
Chung, E. S., Katra, R. P., Ghio, S., Bax, J., Gerritse, B., Hilpisch, K., Peterson, B. J., Feldman, D. S., & Abraham, W. T.
Venue
European Journal of Heart Failure
Published
2010-05-24
Volume
12
Issue
6
Pages
581-587
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2144202315
Cited by
125
References
7
FWCI
10.63
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiac Resynchronization Therapy May Benefit Patients with Left Ventricular Ejection Fraction >35%: A PROSPECT Trial Substudy. https://app.cochat.ai/papers/10.1093/eurjhf/hfq009
The paper
Chung, E. S., Katra, R. P., Ghio, S., Bax, J., Gerritse, B., Hilpisch, K., Peterson, B. J., Feldman, D. S., & Abraham, W. T. (2010). Cardiac Resynchronization Therapy May Benefit Patients with Left Ventricular Ejection Fraction >35%: A PROSPECT Trial Substudy. European Journal of Heart Failure. https://doi.org/10.1093/eurjhf/hfq009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.